Guidance
Our Guidance explains the laws and regulations governing the development, manufacturing, marketing, and supply of therapeutic goods in Australia.
We recently introduced new features to improve your experience using Guidance on our website.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (32)
- Breast implant hub (1)
- Clinical trials (5)
- Committees and advisory bodies (2)
- Compliance and enforcement (30)
- Cosmetics (4)
- COVID-19 (11)
- Fees and payments (3)
- Import and export (9)
- Labelling and packaging (26)
- Legislation (9)
- Manufacturing (41)
- Medicinal cannabis hub (4)
- Metal-on-metal hip replacement implants hub (1)
- Safety monitoring and information (46)
- Scheduling (national classification system) (6)
- Shortages and supply disruptions (3)
- Sunscreens (2)
- Unique Device Identification (UDI) hub (3)
- Vaping hub (5)
- Weight loss products (1)
Search
295 result(s) found, displaying 126 to 150
-
GuidanceGuidance for sponsors, manufacturers and providers of faecal microbiota transplant (FMT) products.
-
GuidanceGuidance explaining regulatory requirements for in-house in-vitro diagnostic medical devices (IVDs).
-
GuidanceGuidance on specific criteria and paperwork required for submission to the TGA to ensure conformance with TGO 93.
-
GuidanceGuidance about how to request reconsideration of 'reviewable' initial decisions by the Minister for Health.
-
GuidanceGuidance applies to self-tests and point-of-care combo test kits.
-
GuidanceGuidance on requirements for Australian market authorisation of a cough expectorant containing guaifenesin, for an OTC new medicine N2 application.
-
GuidanceGuidance on how to prepare your application for orphan drug designation so that it meets eligibility criteria and requirements.
-
GuidanceGuidance for sponsors of faecal microbiota transplant (FMT) products, which are regulated as biologicals.
-
GuidanceGuidance about the process of applying for a priority determination, which is the first step of the priority review registration pathway.
-
GuidanceGuidance for Australian corporations applying to become an Australian Conformity Assessment Body (CAB) for medical devices, including IVDs.
-
GuidanceGuidance on the information that we include in AusPARS for prescription medicines and when we publish them.
-
GuidanceGuidance for the deletion of commercially confidential and personal information in an Australian Public Assessment Report (AusPAR).
-
GuidanceThis guidance is to assist sponsors understand their requirements when supplying ‘unapproved’ therapeutic goods under the Special Access Scheme and Authorised Prescriber Pathway.
-
GuidanceGuidance to help determine whether products are separate and distinct biologicals that will need to be included as separate ARTG entries.
-
GuidanceGuidance on declaring and managing conflicts of interest and confidentiality obligations for TGA advisory committee members.
-
GuidanceAn overview on the application process for manufacturers aiming to obtain a TGA-issued Conformity Assessment certificate.
-
GuidanceThis guidance will assist you in determining if a product is a cosmetic or a therapeutic good and how to comply with Australian regulatory requirements and advertising rules for therapeutic goods.
-
GuidanceGuidance to explain what we need for software and apps that work with COVID-19 rapid antigen tests.
-
GuidanceGuidance on TGO 107: Mandatory labelling requirements for biologicals and human cell and tissue materials.
-
GuidanceGuidance for notifying the TGA about substantial changes to, or transfers of, Conformity Assessment certificates.
-
GuidanceGuidance on applying for a provisional determination, which is the first step of the provisional approval pathway.
-
GuidanceThis guidance explains parts 4 and 5 of the Code, which requires certain information to be prominently displayed or communicated in advertisements for therapeutic goods.
-
GuidanceGuidance to help work out if your autologous HCT product is exempt from some aspects of our regulation.
-
GuidanceThis guidance explains parts 2 and 3 of the Code, which requires advertising about therapeutic goods to be accurate, balanced, safe and not misleading.
-
GuidanceGuidance to help work out if your autologous HCT product is excluded from our regulation.